

Expert Practice in lung cancer

Chair

Solange Peters, MD, PhD – Switzerland

Faculty

Benjamin Besse, MD, PhD – France

Anne-Marie Dingemans, MD, PhD – the Netherlands

Wolfgang Jungraithmayr, MD, PhD – Switzerland

Keith Kerr, MD, FRCPath – United Kingdom

Natasha Leighl, MD, MMSc, FRCPC – Canada

Umberto Ricardi, MD, PhD – Italy

Register online at

www.prIMEoncology.org/EPLung_Prague2014

For available travel grants, please email travelgrants@prIMEoncology.org

Agenda

Saturday, 13 December

- o8.30 Welcome, introduction, and demographics prIME Medical Director and Solange Peters, MD, PhD
- o8.50 The role of pathology in the era of targeted therapy Keith Kerr, MD, FRCPath
- og.20 Keynote lecture—Immunotherapy: A step forward in treatment of advanced NSCLC Solange Peters, MD, PhD
- og.50 Case #1—Stage III NSCLC: What's the best multimodality approach? Wolfgang Jungraithmayr, MD, PhD; Umberto Ricardi, MD, PhD; Benjamin Besse, MD, PhD
- 10.50 Coffee break

Welcome

On behalf of Solange Peters, MD, PhD, meeting chair, we are pleased to invite you to the *Expert PracticeSM in Lung Cancer* meeting in Prague, Czech Republic, on 13 December 2014.

During this case-based meeting, leaders in the field will discuss, in an interactive format, clinical issues encountered daily by practicing physicians.

Target Audience

This educational activity is intended for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, and other oncology professionals interested and/or involved in the management of patients with non-small cell lung cancer (NSCLC).

Meeting Venue

andel's Hotel Prague

Stroupežnického 21 150-00 Prague 5 Czech Republic

- 11.10 Case #2—Advanced NSCLC: Treatment strategies in the absence of targetable driver mutations Benjamin Besse, MD, PhD
- 11.55 Case #3—Adenocarcinoma with ALK rearrangement: Selecting optimal approach Natasha Leighl, MD, MMSc, FRCPC
- 12.40 Lunch
- 13.40 Clinical opinion poll questions: Challenging the experts
- 14.10 Case #4—EGFR-mutated advanced NSCLC: Evaluating treatment options Anne-Marie Dingemans, MD, PhD
- 14.55 Case #5—Squamous cell lung carcinoma: The changing treatment paradigm
 Natasha Leighl, MD, MMSc, FRCPC
- 15.40 Concluding remarks
 Solange Peters, MD, PhD

